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Resistant mouse strains mount a protective T  cell-mediated immune response upon 
infection with Leishmania (L.) parasites. Healing correlates with a T helper (Th) cell-type 
1 response characterized by a pronounced IFN-γ production, while susceptibility is 
associated with an IL-4-dependent Th2-type response. It has been shown that dermal 
dendritic cells are crucial for inducing protective Th1-mediated immunity. Additionally, 
there is growing evidence that C-type lectin receptor (CLR)-mediated signaling is involved 
in directing adaptive immunity against pathogens. However, little is known about the 
function of the CLR Dectin-1 in modulating Th1- or Th2-type immune responses by 
DC subsets in leishmaniasis. We characterized the expression of Dectin-1 on CD11c+ 
DCs in peripheral blood, at the site of infection, and skin-draining lymph nodes of L. 
major-infected C57BL/6 and BALB/c mice and in peripheral blood of patients suffering 
from cutaneous leishmaniasis (CL). Both mouse strains responded with an expansion of 
Dectin-1+ DCs within the analyzed tissues. In accordance with the experimental model, 
Dectin-1+ DCs expanded as well in the peripheral blood of CL patients. To study the 
role of Dectin-1+ DCs in adaptive immunity against L. major, we analyzed the T  cell 
stimulating potential of bone marrow-derived dendritic cells (BMDCs) in the presence 
of the Dectin-1 agonist Curdlan. These experiments revealed that Curdlan induces the 
maturation of BMDCs and the expansion of Leishmania-specific CD4+ T cells. Based on 
these findings, we evaluated the impact of Curdlan/Dectin-1 interactions in experimental 
leishmaniasis and were able to demonstrate that the presence of Curdlan at the site 
of infection modulates the course of disease in BALB/c mice: wild-type BALB/c mice 
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treated intradermally with Curdlan developed a protective immune response against 
L. major whereas Dectin-1−/− BALB/c mice still developed the fatal course of disease after 
Curdlan treatment. Furthermore, the vaccination of BALB/c mice with a combination 
of soluble L. major antigens and Curdlan was able to provide a partial protection from 
severe leishmaniasis. These findings indicate that the ligation of Dectin-1 on DCs acts as 
an important checkpoint in adaptive immunity against L. major and should therefore be 
considered in future whole-organism vaccination strategies.
Keywords: curdlan, β-glucan, Dectin-1, cutaneous leishmaniasis, adaptive immunity, dendritic cells, T helper 1 and 
T helper 2 cells
inTrODUcTiOn
Cutaneous leishmaniasis (CL) is a vector-borne parasitic infec-
tious disease encountered in tropical and subtropical regions of 
the world (1). The causative agents are flagellated protozoans of the 
genus Leishmania (L.), which are inoculated into the skin during 
the blood meal of female sandflies. Different clinical manifesta-
tions in humans, ranging from a self-limiting cutaneous infection 
to disseminating visceral leishmaniasis (VL), are described with 
respect to the transmitting vectors and Leishmania species (2).
Comparable to the course of disease in humans, L. major 
parasites can develop cutaneous manifestations in C57BL/6 and 
BALB/c mouse models (3). The infection of inbred mice with 
stationary phase promastigote Leishmania parasites allowed the 
examination of basic mechanisms, resulting in innate and adap-
tive T cell-mediated immunity (3).
It is known that L. major parasites require phagocytic cells 
for replication and spreading within the host (4). In this regard, 
neutrophils and macrophages play a pivotal role as host cells for 
the initial survival and spreading of parasites. However, mac-
rophages produce leishmanicidal molecules after appropriate 
activation by certain T helper (Th) 1 cytokines such as IFN-γ (3, 
5) and become effector cells during the host response against 
L. major. Thus, healing of CL in C57BL/6 mice is associated 
with a pronounced expansion of IFN-γ-secreting Th1  cells 
(6), whereas susceptibility of BALB/c mice is associated with 
a diminished IFN-γ, but increased IL-4-production in high-
dose infection models (5, 7, 8). Therefore, CD4+ T  cells are 
crucial key players in modulating antigen-specific immunity 
in leishmaniasis (3).
It is mostly accepted that Th1- and Th2-effector cells derive 
from a common CD4+ T  cell precursor (9). Several stimuli 
have been reported to influence the pathway of maturation 
of these CD4+ T  cell progenitors (10). Using CD4+ T  cells, 
transgenic for a unique TCR alpha/beta receptor, it was proven 
that distinct cytokines such as IL-12 and IL-4 are crucial for 
the polarization of Th1 and Th2 cells (5, 10). Th1  cell dif-
ferentiation takes place after Leishmania-specific T cells have 
been primed sufficiently by antigen-presenting cells in skin-
draining lymph nodes (SDLNs) (11). Based on the current 
model it must be assumed that Langerin− dermal dendritic 
cells (dDCs) are pivotal for the induction of the protective 
Th1-mediated immune response against L. major in C57BL/6 
mice (12–14). Of note, Langerin+ epidermal Langerhans cells 
are dispensable for the generation of protective immunity in 
experimental leishmaniasis (13–16).
T cell-mediated immunity against L. major parasites is a mul-
tistep process whereby mature DC subsets are pivotal to start the 
adaptive immune response within SDLNs (12, 14). Maturation 
of DCs is accompanied by high expression of chemokine recep-
tor (CCR) 7, paving the way to the SDLN and costimulatory 
molecules crucial for DC/T-cell communication (17). Certain 
cytokines such as TNF-α and IL-6 are known to support this pro-
cess (17, 18). Additionally, pattern recognition receptors (PRRs) 
binding pathogen components are also potent activators of DC 
maturation (19). Especially toll-like receptors that represent the 
most popular PRRs (20), recognize pathogen-associated molecu-
lar patterns derived from various pathogens, including viruses, 
bacteria, fungi, parasites, and protozoa, and are crucial for innate 
immune mechanisms (21).
The C-type lectin receptors (CLRs) also belong to PRRs and 
recognize predominantly carbohydrates and non-carbohydrates 
through mechanisms that are still not fully understood (22). The 
CLR Dectin-1 recognizes β-glucans (22–25) that naturally occur 
in the cell wall of fungi (23). In addition to pathogen-derived 
factors, endogenous N-glycans present on the surface of tumor 
cells also represent potential Dectin-1 ligands and trigger tumor 
killing by NK cells (26).
Mouse Dectin-1 is expressed by various immunologically 
relevant cells belonging to the adaptive and innate immune sys-
tem. Preferentially, monocytes, macrophages, neutrophils, and a 
subset of T cells were described to be positive for Dectin-1 (27). 
There is growing evidence that engagement of Dectin-1 on DC 
subsets is crucial for T-cell polarization in experimental mouse 
models (28, 29). In humans, Dectin-1 is widely expressed by all 
monocyte populations as well as by macrophages, DC, neutro-
phils, eosinophils, and B cells (27, 30). In line with these findings, 
it was shown that the function of human Dectin-1 is equivalent to 
that of mouse Dectin-1 (30). Thus, CLRs in general and Dectin-1 
in particular might be considered as important checkpoints for 
adaptive immune responses.
It could be demonstrated that Dectin-1−/− macrophages from 
C57BL/6 mice show a slightly reduced capacity for phagocytosis 
of L. infantum parasites in vitro (31). Thus, Dectin-1 might be 
involved in the formation of parasitophorous vacuoles (32). In 
line with these findings, it is important to mention that infected 
macrophages from C57BL/6 show an enhanced expression 
of Dectin-1 after infection with L. amazonensis in  vitro (33). 
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Consequently, the pronounced Dectin-1 expression by infected 
myeloid cells might potentiate the uptake of parasites and favors 
the spreading of the obligatory intracellular parasites during 
the first stage of innate immunity. An interaction of Dectin-1 
with parasite-derived carbohydrates was not identified so far. 
Nevertheless, β-glucan can activate infected macrophages from 
BALB/c mice to control the replication of L. donovani parasites 
in  vitro (34, 35). Additionally, it was shown that NK  cells can 
also be activated by Aureobasidium-derived soluble branched 
(1,3–1,6)-β-glucan that results in enhanced cellular immunity 
against L. amazonensis parasites in BALB/c mice (36). The 
scientific evidence, that β-glucan can modulate innate immune 
mechanisms against L. major parasites at the site of infection, is 
still pending.
Dectin-1 signaling is also discussed to be crucial in direct-
ing adaptive T  cell-mediated immune responses. Thus far, it is 
known that Dectin-1 ligation by fungal components triggers 
Th1- and Th17-mediated immune responses against fungi 
(37–41). Accordingly, Dectin-1 deficiency results in impaired 
T  cell-mediated immunity and loss of control of fungal infec-
tion (42). Long before Dectin-1 was described as a receptor for 
β-glucans, these glucose polysaccharides were used as adjuvants 
for immunization and systemic therapies of VL in BALB/c and 
C57BL/6 mice (43–47). In line with this, Ghosh et al. were able 
to efficiently treat BALB/c mice infected with L. donovani by 
multiple intraperitoneal (i.p.) applications of the linear β-glucan 
Curdlan, which induced Th17-mediated adaptive immunity and 
macrophage activation (34). Most of the studies investigating 
the effect of β-glucans were carried out using VL-causing L. 
donovani parasites. However, one study is published demonstrat-
ing that multiple systemic applications (i.p. and i.v.) of β-glucan 
after infection of BALB/c mice with L. major parasites blocked 
lesion development or parasite spreading in normally susceptible 
BALB/c mice (48). Whether Dectin-1 is responsible for the 
observed immunological phenomenon has not been shown 
until now. Furthermore, quantification and characterization of 
Dectin-1+ DCs in experimental leishmaniasis and in patients 
suffering from CL are missing.
In this study, we investigated the potential impact of 
β-glucan and of Dectin-1 on DC physiology and subsequent 
modulation of T-cell immunity. Here, we were able to demon-
strate an expansion of Dectin-1+ DCs in experimental leish-
maniasis as well as in patients suffering from CL. Additional 
studies revealed that intradermal application of L. major 
parasites in combination with Curdlan changes the course of 
leishmaniasis: BALB/c mice treated with Curdlan developed 
a protective immune response against L. major, whereas 
Dectin-1−/− BALB/c mice still suffered from a fatal course of 
disease after Curdlan treatment. Based on these data, it appears 
that Dectin-1/Curdlan interactions per  se are sufficient to 
modulate Th-cell differentiation. Further in vitro studies were 
performed to explore the cellular mechanisms. One important 
finding was the change in the phenotype and functionality of 
infected DCs triggered by Curdlan. They increase the expres-
sion of Dectin-1 and costimulatory molecules and become 
potent antigen-presenting cells, capable of accelerating the 
expansion of L. major-specific T cells.
The results presented in this article support the view that 
Dectin-1+ DCs represent promising targets for modulating 
adaptive T  cell-mediated immunity and should therefore be 
considered in future whole-organism vaccination strategies.
MaTerials anD MeThODs
human samples
7–10 mL of peripheral blood samples were collected from patients 
suffering from CL and Ethiopian healthy controls (EHCs) living 
in Oromo and Amhara regions of Ethiopia. The sample collection 
was permitted based on the local ethical committee (allowance 
number PO25/08, Addis Ababa, Ethiopia) and the national health 
research ethics review committee (approval number 310/227/07, 
Addis Ababa). Written informed consent was obtained from 
the participants of this study. CL was confirmed by positive 
parasite cultures and PCR analysis as described elsewhere (49). 
CL patients were excluded from the study if they show one of 
the following criteria: younger than 18 and older than 55 years, 
chronic lesions (more then 6 months), positive for HIV, clinical 
evidence for coinfections, and drug intake.
Mice
Female wild-type BALB/c and C57BL/6 mice (Janvier Labs, 
Le Genest St. Isle, France) were kept at the animal facility of 
the University of Regensburg under pathogen-free conditions. 
Dectin-1−/− mice on BALB/c background [kindly provided 
by G.D. Brown, University of Aberdeen (50)] were bred and 
maintained under conventional animal housing conditions. All 
experiments and animal housing were performed according to 
the guidelines for the care and use of experimental animals. The 
animal work was approved by the local veterinary authorities 
of the district government based on the European guidelines 
and national regulations of the German Animal Protection Act 
(approval no. AZ 54-2532.105/11). Female animals between 6 
and 12 weeks of age were used for experiments.
Parasites and infection of Mice
Virulent L. major parasites (MHOM/IL/81/FE/BNI) were 
propagated in vitro in blood agar cultures as described previ-
ously (51). Stationary phase promastigotes from the third to 
seventh in  vitro passage were harvested, washed four times, 
and resuspended in PBS. Mice were infected via intradermal 
injection of 3 ×  106 stationary phase promastigotes in 30  µL 
into the hind footpads. The increase in lesion size was moni-
tored weekly by measuring the footpad thickness with a metric 
caliper (Kroeplin Schnelltaster, Schlüchtern, Germany). The 
increase in footpad thickness (%) was determined as described 
elsewhere (52).
curdlan application
Curdlan (WAKO Chemicals GmbH, Neuss, Germany) was 
dissolved in sterile PBS to a concentration of 50 µg/µL. 3 × 106 
stationary phase promastigotes were resuspended in 30  µL 
of Curdlan solution and injected intradermally into the hind 
footpads. Alternatively, soluble L. major antigens [SLA; (15)] 
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corresponding to 3 ×  106 stationary phase promastigotes were 
used. The course of disease was monitored as described earlier.
Quantification of L. major-specific  
igg subtypes
Serum from naïve mice and from mice infected with L. major 
parasites was prepared at the corresponding time point and there-
after stored at −20°C until use. Detection of L. major-specific 
IgG1 (Invitrogen, Darmstadt, Germany), IgG2a (BD Pharmingen, 
Heidelberg), and IgG2c (Jackson ImmunoResearch, Hamburg 
Germany) isotypes were performed as described earlier (53). 
The results were standardized by calculation of relative ELISA 
units (REU). REU were determined by the formula: OD450 serum 
(infected mice)/OD450 serum (naïve mice).
Delayed-Type hypersensitivity (DTh) 
reaction
Three weeks after L. major infection, SLA (corresponding to 
3 × 106 parasites) was injected in a volume of 20 µL in the foreleg. 
As a control, 20  µL of PBS was injected in the contra lateral 
foreleg. The increase in swelling was measured with a metric 
caliper (Kroeplin Schnelltaster) and referred to the control fore-
leg. The swelling was measured with a metric caliper (Kroeplin 
Schnelltaster) after 24, 48, and 72 h.
generation of Bone Marrow-Derived 
Dendritic cells (BMDcs)
Bone marrow-derived dendritic cells were generated as previously 
described (54). Bone marrow cells from C57BL/6 or BALB/c mice 
were seeded in 10 cm BD Tissue culture dishes at a density of 
2 × 106 per dish in 10 mL of RPMI medium supplemented with 
10% fetal calf serum (FCS; PAN Biotech GmbH), penicillin–strep-
tomycin, 50 µM β-ME, and 10% GM-CSF containing supernatant 
harvested from Ag8653 myeloma cells transfected with the gene 
encoding murine GM-CSF (kindly provided by B. Stockinger, 
NMRI, Mill Hill, London, UK). BMDCs were harvested on day 
10 for T cell proliferation experiments.
generation of Bone Marrow-Derived 
Macrophages (BMDMs)
Mouse BMDMs were generated from female BALB/c mice and 
cultured for 7 days in hydrophobic Teflon bags (FT FEP 100C 
Dupont, American Durafilm, Holliston, MA) as described earlier 
(55, 56). For killing experiments, BMDMs were pulse-infected 
with L. major promastigotes at a 1:30 ratio for 4 h as described 
earlier (56). After infection, extracellular promastigotes were 
removed by washing with PBS and cultured in the absence or 
presence of Curdlan (50, 100, and 250  µg/mL) or LPS/IFN-γ 
(10 and 20  ng/mL, respectively). After 72  h, BMDMs were 
fixed, stained, and analyzed microscopically using Diff-Quick 
staining (Medion Diagnostics, Düdingen, Switzerland) for the 
determination of the percentage of infected cells and the num-
ber of parasites per infected cell. LPS (Escherichia coli O111:B4) 
was purchased from Sigma-Aldrich (Taufkirchen, Germany). 
Recombinant murine IFN-γ was purchased from eBioscience 
(Frankfurt, Germany).
nitrite accumulation
Nitrite accumulation in the supernatants was determined as an 
indicator for NO activity after stimulation of BMDMs using the 
Griess reaction as described earlier (56).
labeling of Leishmania Parasites with 
cFse
Stationary phase promastigotes from the third to seventh in vitro 
passage were harvested, washed four times, and resuspended in 
PBS. After lysis of the remaining erythrocytes, parasites were 
labeled by incubation in 1 µM CFSE staining solution as described 
earlier (57).
Leishmania-specific T cell Proliferation 
assay
C57BL/6 and BALB/c mice were infected with L. major para-
sites as described earlier. Ten days post infection, SDLNs were 
removed, and T cells were enriched untouched via MACS sepa-
ration columns (Miltenyi Biotec, Bergisch Gladbach) according 
to the manufacturer’s guidelines. Single-cell suspensions were 
labeled with PE-conjugated CD11b, CD11c, and B220 antibodies 
(Abs) and subsequently detected with anti-PE Beads (Miltenyi 
Biotec) in order to deplete myeloid cells and B cells. The purified 
T cells were labeled with CFSE as described earlier (15). 2 × 105 
CFSE-labeled T  cells were seeded in 96-well round-bottom 
plates (Nunc) to 2 × 104 BMDCs that have been primed for 24 h 
with SLA (as an equivalent of 5 parasites: 1 BMDC) or L. major 
parasites (10 parasites: 1 BMDC) in the presence or absence 
of Curdlan (50 μg/200 μL). 72 h after coculture, the cells were 
analyzed by flow cytometry. The proliferation index of samples 
was calculated according to the formula: (number of proliferat-
ing cells after stimulation)/(number of proliferating cells in the 
absence of stimulation). The proliferation index of stimulated 
samples was then normalized to that of unstimulated BMDC/T-
cell cultures. Supernatants were collected and stored at −80°C for 
cytokine analysis.
clr-Fc Fusion Protein staining of 
Parasites
The CLR-Fc fusion proteins (Dectin-1, CLEC-9a, and MGL-1) 
were prepared as described previously (58). After blocking 
(PBS/10% FCS/10% mouse serum), L. major parasites were 
washed three times in PBS. To analyze interactions with CLRs, 
parasites were incubated with 20 µg/mL of CLR-Fc fusion proteins 
diluted in lectin binding buffer (50 mM HEPES, 5 mM MgCl2, 
and 5 mM CaCl2, in dH2O, pH 7,4) at 4°C for 1 h. After three 
washing steps with PBS, CLR-Fc binding to L. major was detected 
with a FITC-conjugated goat anti-hFc Ab (Dianova, Hamburg, 
Germany). Parasite DNA was detected with 6-diamidino-2-phe-
nylindole obtained from Sigma Aldrich, as described earlier (59). 
After mounting with PermaFluor (Thermo Scientific, Dreieich, 
Germany), the sections were analyzed using Axio Imager.M1 
(Zeiss, Jena, Germany) equipped with high-sensitivity gray scale 
digital camera (AxioCam MRm, Zeiss). Separate images were col-
lected for each section, analyzed, and merged afterward (acquisi-
tion software: Zeiss AxioVision 4.6.3). Final image processing for 
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illustrations was performed using Adobe Photoshop Elements 
(Adobe Systems GmbH, Munich, Germany).
Flow cytometry analysis of Mouse 
samples
Single-cell suspensions of tissues were generated as described 
elsewhere (60). The following Abs and reagents were used for 
phenotyping of single-cells: PE-labeled anti-mouse CD11c Ab 
(clone N418; eBioscience, Frankfurt, Germany), APC-labeled 
anti-mouse CD11b (clone M1/70, eBioscience, Germany), 
PE-labeled anti-mouse F4/80 (clone 521204, R&D), biotinylated 
anti-mouse Dectin-1 Ab (clone 2A11; Bio-Rad AbD Serotec 
GmbH, Puchheim, Germany), AlexaFluor647-labeled anti-
mouse CD86 Ab (clone GL-1; BioLegend, San Diego, CA, USA), 
and FITC-labeled anti-BrdU Ab (clone B44; BD Pharmingen, 
Heidelberg, Germany). Depending on the experimental setup, 
the detection of biotinylated anti-mouse Dectin-1 was performed 
using streptavidin-conjugated to V500 (BD, Pharmingen, 
#561419), eFluor450 (eBioscience, #48-4317-82), Pacific Orange 
(Thermo Fisher, Munich, Germany), or PerCP (BD, Pharmingen, 
#554064). Ab specificity was verified using appropriate isotype 
controls and Dectin-1−/− mice (Figure S1 in Supplementary 
Material). Multicolor flow cytometry was performed as described 
previously (13). Mice were fed with BrdU-containing drinking 
water (0.8  mg/mL, Sigma, Deisenhofen, Germany) starting 
3 days before the termination of the experiment. BrdU labeling 
was performed according to the manufacturer’s instructions (BD 
Pharmingen, Heidelberg, Germany). After labeling of surface 
epitopes, the cells were fixed and permeabilized with Cytofix/
Cytoperm buffer (BD Pharmingen, Heidelberg, Germany) for 
30 min on ice and afterward incubated for 10 min on ice with 0.01% 
Triton X-100 (SERVA, Heidelberg, Germany) in PBS/0.1% BSA 
(PAN, Aidenbach, Germany). For the detection of incorporated 
BrdU, the cells were treated with 30 µg DNAse (Sigma, Munich, 
Germany) for 1 h at 37°C. Labeling of cells with anti-BrdU Ab was 
performed for 20 min at room temperature. Cells were collected 
using BD™ LSRII Flow Cytometer (BD Biosciences, Heidelberg, 
Germany) and analyzed with FlowJo software (Tree Star Inc., 
Ashland, OR, USA). The determination of the total cell numbers 
in tissues was performed as described earlier (61).
Flow cytometry analysis of human 
samples
Surface antigens were detected on fresh cells using a modified 
version of the method described by Aldebert et al. (62). 7–10 mL 
of blood from patients and EHCs were taken with BD Vacutainer 
(BD Biosciences, UK) containing 170  IU of lithium heparin. 
200 µL of whole blood cells was incubated for 20 min with FcR 
blocking reagent (Miltenyi Biotec GmbH, Germany). The stain-
ing was performed for 30  min at 4°C. The following Abs were 
used: FITC-labeled anti-lineage (Lin) panel (CD3, CD14, CD16, 
CD19, CD20, and CD56) (BD), PerCP-labeled anti-HLA-DR 
(R&D, clone L203), PE-labeled anti-CD123 (R&D, clone 32703), 
PE-Cy5.5-labeled anti-CD11c (BD, clone B-Ly6), and APC-
labeled anti-Dectin-1 (R&D, clone 259931). Erythrocytes were 
lysed with BD FACS™ Lysing Solution (BD Biosciences), and 
the remaining white blood cells were washed and resuspended in 
FACS buffer (PBS buffer, pH 7.2 1% BSA fraction V, Roth, 8076.2), 
0.01% NaN3 (Sigma: S2002-25G), and 1% human serum. A total 
of 200,000 events were acquired and the positive population gated 
using the isotype controls for the different fluorochromes. Data 
were acquired with a FACS Canto flow cytometer (BD Bioscience). 
Data analysis was performed with FlowJo 8.8.6.
gene expression analysis by  
Quantitative rT-Pcr
CD4+ T  cells were sorted with the CD4+ Cell isolation Kit® 
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
the manufacturer’s specification. Following cell sorting, the 
CD4+ cells were lysed in 350 µL Buffer RA1 (Macherey-Nagel, 
Düren, Germany) supplemented with 3.5 µL β-ME. Total RNAs 
were isolated using the NucleoSpin® RNA kit (Macherey-Nagel), 
following the manufacturer’s instructions. RNAs were quanti-
fied by spectrophotometry and 170  ng of RNAs were used for 
cDNA synthesis using the iScript cDNA Synthesis kit (Bio-Rad 
Laboratories, München, Germany), as recommended by the 
manufacturer. Quantitative PCR was performed on a RotorGene Q 
(Qiagen, Hilden, Germany) using a two-step PCR program (95°C 
15 s, 60°C 60 s; 40 cycles). 20 µL quantitative PCR reactions were 
performed using 0.3–0.6 µL of cDNA template (corresponding to 
2.5–5 ng RNA equivalent) and a self-made master-mix containing 
SYBR Green I and HotStarTaq DNA Polymerase (Qiagen). Data 
were normalized to GAPDH mRNAs and expressed as relative 
mRNA levels, as previously reported (63, 64). Forward (fwd) and 
reverse (rev) mouse-specific quantitative PCR primers were as 
follows: GAPDH, 5′-AGCTTGTCATCAACGGGAAG-3′ (fwd) 
and 5′-TTTGATGTTAGTGGGGTCTCG-3′ (rev); GATA, 5′-CC 
AAGGCACGATCCAGCACAGA-3′ (fwd) and 5′-GGCCGACA 
GCCTTCGCTTGG-3′ (rev); IFNG, 5′-AGGTCAACAACCCAC 
AGGTCC-3′ (fwd) and 5′-GATTCCGGCAACAGCTGGT-3′ 
(rev); IL-4, 5′-ACAGGAGAAGGGACGCCAT-3′ (fwd) and 5′-GA 
AGCCCTACAGACGAGCTCA-3′ (rev); IL-17A, 5′-AACTCCCT 
TGGCGCAAAAG-3′ (fwd) and 5′-GAGAGTCCAGGGTGACG 
TGG-3′ (rev); STAT4, 5′-CCTGGGTGGACCAATCTGAA-3′ 
(fwd) and 5′-CTCGCAGGATGTCAGCGAA-3′ (rev); STAT6, 
5′-CCCCAACAAACTTCTCATCCA-3′ (fwd) and 5′-TTTGGC 
GTTGTTGTCTTGGTT-3′ (rev); and T-BET, 5′-ACCAACAACA 
AGGGGGCTCT-3′ (fwd) and 5′-CTCTGGCTCTCCATCATTC 
ACC-3′ (rev).
Quantification of L. major Parasites
To measure the parasite burden, genomic DNA was isolated 
using DNA purification solutions from QIAGEN (QIAGEN, 
Hilden, Germany). In brief, the cells were digested in cell lysis 
solution directly in the well. Protein was removed by adding 
protein precipitation buffer, and DNA was precipitated accord-
ing to the manufacturer’s instructions with 100% 2-propanol 
(Sigma Aldrich, Taufkirchen, Germany). The concentration of 
mouse β-actin-DNA was quantified by PCR (65). The Leishmania 
DNA concentrations in the same samples were determined using 
fluorescence resonance energy transfer real-time PCR with 
Leishmanial 18S ribosomal DNA sequences (66). The resulting 
FigUre 1 | Characterization of Dectin-1+ DC subsets in blood samples from 
patients suffering from cutaneous leishmaniasis (CL). Peripheral blood 
samples from patients suffering from CL and Ethiopian healthy controls 
(EHCs) were stained for CD11c, Dectin-1, HLA-DR, CD123, and a lineage 
cocktail (anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD20, and 
anti-CD56) abbreviated as Lin. The following gating strategy was used. (a) 
FSC and SSC plots were used to define the leukocyte population. (B) 
Lin− cells were selected for further analysis. (c) Lin− cells were differentiated 
into CD11c+/CD123−/int and CD11c−/CD123bright populations displayed as dot 
plot. (D) The histogram plot indicates the expression of Dectin-1 on CD11c+/
CD123−/int (highlighted in red) and CD11c−/CD123bright cells (highlighted in 
blue). The black line represents the isotype control. (e,F) The frequency of 
Dectin-1+ cells within the indicated subset is shown by box plot diagrams. 
Number of analyzed donors, n = 5. Data were analyzed using Student’s t-test 
(**p = 0.004).
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Leishmania DNA copy number was then divided by the copy 
number of β-actin-DNA to obtain the relative parasite units 
(RPU).
Quantification of cytokines
Supernatants of cell cultures were analyzed with a FlowCytomix™ 
kit (IL-13, IL-1α, IL-22, IL-2, IL-21, IL-6, IL-10, IL-27, IFN-γ, 
TNF-α, IL-4, and IL-17) according to the manufacturer’s (eBio-
science, Thermo Fisher Scientific, Waltham, USA) specifications. 
Acquisition of probes was performed with a FACS Canto II (BD 
Bioscience).
statistical analysis
Statistical significance between groups were calculated by differ-
ent tests: two-way ANOVA for comparing the footpad swelling 
of analyzed groups, non-parametric Mann–Whitney tests if no 
normal distribution (no Gaussian distribution) was determined, 
and two-tailed Student’s t-test if normal distribution (Gaussian 
distribution) was determined. The calculation was performed 
using PRISM software (GraphPad, La Jolla, CA, USA). The cor-
responding p values are highlighted by stars only if p < 0.050.
resUlTs
local infection with Leishmania  
Parasites results in systemic expansion 
of Dectin-1+ Dcs in Patients suffering 
from cl
DCs are known to be important checkpoints for the generation 
of T  cell-mediated protective immunity in experimental leish-
maniasis (67). Based on the potential role of Dectin-1+ DCs in 
adaptive immunity, we addressed the question whether a cutane-
ous infection with Leishmania parasites results in an expansion 
of Dectin-1+ DCs.
In humans, it is difficult to analyze the dynamics of DC popu-
lations in tissues or secondary lymphoid organs. Therefore, we 
focused on the analyses of blood samples. DCs in the peripheral 
blood lack certain Lin-specific markers (68). Thus, Lin− leu-
kocytes were used for further characterization of human DCs 
(Figures 1A,B). The Lin− population consists of HLA-DR− and 
HAL-DR+ cells (Figure 1B). In accordance with other published 
data, the Lin− CD11c+ cells are positive for HLA-DR and could 
be found within the Lin−/HLA-DR+ population (68, 69) (data not 
shown).
On the basis of the markers CD11c and CD123 (68, 70) mye-
loid DCs (mDC; CD11c+/CD123−/int) were dissected from plas-
macytoid DC (pDC; CD11c−/CD123bright) subsets (Figure  1C). 
We could demonstrate that pDCs from EHCs and CL patients 
hardly express Dectin-1 (Figure 1D). The expression of Dectin-1 
is predominantly restricted to mDCs (Figure  1D). Cutaneous 
infection with Leishmania parasites results in an increased fre-
quency of Dectin-1+-positive mDCs in the periphery compared 
to healthy controls (Figure 1E). Of note, the pDC subset does 
not show significant differences in Dectin-1 expression between 
EHCs and patients suffering from CL (Figure  1F). These data 
suggest that a local infection with Leishmania parasite results in 
the expansion of Dectin-1+ mDC subsets in the peripheral blood 
of CL patients.
local infection with Leishmania Parasites 
results in systemic Proliferation of 
Dectin-1+ Dcs in BalB/c and c57Bl/6 
Mice
CD11c is hardly expressed by pDCs in mouse models (71, 72). 
Thus, most of the CD11c+/bright DCs belong to the subset of 
FigUre 2 | Characterization of Dectin-1 expression on proliferating 
CD11c+ DCs in blood samples of infected C57BL/6 and BALB/c mice. 
Mice were infected intradermally with Leishmania major parasites into the 
hind footpad, and the peripheral blood was analyzed 13 days after 
infection. Naïve mice served as controls (day 0). BrdU+ was given 3 days 
before the analysis. Peripheral blood leukocytes were gated. (a) The dot 
plot diagram displays the CD11c and BrdU intensities. BrdU+/CD11c+ cells 
are highlighted by a red and BrdU−/CD11c+ by a blue gate. (B) Dectin-1 
expression of the BrdU subsets is shown as histogram displaying isotype 
control in black, BrdU+/CD11c+ cells in red, and BrdU−/CD11c+ cells in 
blue line. (c) The frequencies of Dectin-1+/CD11c+ cells (blue bars, BrdU−/
CD11c+; red bars, BrdU+/CD11c+) within the peripheral blood of C57BL/6 
mice were analyzed. Pooled data from three different experiments are 
shown (mean ± SD). Data were analyzed using Student’s t-test 
(**p = 0.004, ***p = 0.0003). (D) The frequencies of Dectin-1+/CD11c+ 
cells (blue bars, BrdU−/CD11c+; red bars, BrdU+/CD11c+) within the 
peripheral blood of BALB/c mice are indicated (mean ± SD). Pooled data 
from three different experiments were analyzed using the non-parametric 
Mann–Whitney test (*p < 0.5).
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conventional DCs including other mDC subsets (73, 74). In CL 
patients, Dectin-1+ mDCs expand after infection. To prove the 
concept that a local infection also results in a systemic expansion 
of Dectin-1+ mDCs, C57BL/6 and BALB/c mice were infected 
intradermally with L. major parasites. SDLNs, the site of infection, 
and the peripheral blood were analyzed for proliferating Dectin-1+ 
CD11c+/bright DCs. Mice were administered the thymidine analog 
BrdU, as described in Section “Materials and Methods,” to analyze 
cell proliferation in  vivo. 13  days after infection, when clinical 
symptoms such as footpad swelling occur and Leishmania-specific 
T  cell-mediated immunity is initiated (13, 60), Dectin-1 was 
measured on BrdU+ (proliferating) and BrdU− (resting) CD11c+ 
DCs (Figures 2A,B). Detailed quantification of Dectin-1+ DCs 
within proliferating and resting CD11c+ DCs revealed that both 
subsets express Dectin-1. However, the frequency of Dectin-1+ 
CD11c+ DCs is substantially higher within the proliferating sub-
set compared to the resting CD11c+ DCs of BALB/c and C57BL/6 
mice (Figures 2C,D). Further analysis of the site of infection and 
SDLNs of infected BALB/c and C57BL/6 mice confirmed this 
result (Figures S2A,B in Supplementary Material). These data 
generated from mice reflect the results obtained in CL patients, 
indicating that a local infection with Leishmania parasites results 
in a systemic expansion of Dectin-1+ DCs.
The Presence of curdlan at the site of 
infection results in an adaptive immune 
response in normally susceptible BalB/c 
Mice
So far, only systemically (i.p. and/or i.v.) applied β-glucans have 
been used to treat BALB/c or C57BL/6 mice after infection 
(34, 43–48). No published data exist analyzing the effects of 
cutaneous application of β-glucan such as Curdlan in paral-
lel to L. major infection. Given that Dectin-1+ DCs expand 
at the site of infection and within SDLNs (Figure  2; Figure 
S2 in Supplementary Material), it seems feasible that a local 
stimulation of Dectin-1+ DCs with Curdlan modulates the 
parasite-specific immune response. To test this hypothesis, 
BALB/c and C57BL/6 mice were infected with promastigote 
parasites suspended in PBS plus Curdlan. The course of infec-
tion was not substantially modulated in resistant C57BL/6 mice 
(Figure S3 in Supplementary Material). In contrast, normally 
susceptible BALB/c mice showed a resistant phenotype when 
the parasites were intradermally injected in combination with 
Curdlan (Figure 3A). BALB/c mice infected with L. major alone 
displayed the well-known severe course of disease (Figure 3A). 
An additional control experiment with Dectin-1−/− BALB/c was 
performed to confirm the specificity of the Curdlan/Dectin-1 
interaction in vivo. Here, we were able to demonstrate that an 
application of Curdlan together with the parasites does not result 
in protective immunity against L. major parasites as shown in 
protected BALB/c wild-type mice (WT) (Figure 3A; Figure S4 
in Supplementary Material). The experiments with non-healing 
BALB/c WT and Dectin-1−/− mice had to be terminated based 
on the severe ulcerated footpads.
C57BL/6 mice usually resolve a primary infection with 
L. major. Following resolution of the primary infection, they are 
immune to reinfection due to the generation of antigen-specific 
memory T  cells (75, 76). To test whether Curdlan-protected 
BALB/c mice (Figure  3A) show classical signs of adaptive 
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FigUre 3 | Continued
immunity, reinfection experiments were performed. BALB/c 
mice that had received Curdlan intradermally in the absence of 
parasites were used to exclude the possibility of an unspecific 
expansion of T cells potentially mediating protection. Resistant 
BALB/c mice, that had been infected with L. major parasites in 
the presence of Curdlan, were reinfected into the contra lateral 
footpad at day 131 after primary infection with a high-dose of 
parasites in the absence of Curdlan. At this time point, no clinical 
signs such as footpad swelling were detectable. BALB/c mice 
that have been treated intradermally only with Curdlan 131 days 
before the primary infection developed a severe course of dis-
ease, that is, comparable to infected BALB/c mice that were not 
pretreated (Figure 3B). In contrast, protected BALB/c mice, that 
resolved the primary infection, were able to rapidly control the 
second round of a high-dose infection with Leishmania parasites 
in the absence of Curdlan (Figure  3B). These mice now show 
FigUre 3 | The presence of Curdlan at the site of infection results in an adaptive immune response in normally susceptible BALB/c. (a) BALB/c control mice were 
infected intradermally with Leishmania (L.) major into the right footpad (black line, black squares; 3 × 106 parasites/30 μL; n = 19), abbreviated as BALB/c plus LM. 
Another group of BALB/c mice was infected with 30 µL of mixture of 3 × 106 parasites and Curdlan (c = 50 μg/μL, blue line, black circles; n = 16), abbreviated as 
BALB/c plus LM/Curdlan. BALB/c mice deficient for Dectin-1 were also infected with 30 µL of a mixture of 3 × 106 parasites and Curdlan (c = 50 µg/µL, red line, 
black circles; n = 5), abbreviated as BALB/c Dectin-1−/− plus LM/Curdlan. Based on severe necrosis of the infected footpads, the groups BALB/c plus LM and 
BALB/c Dectin-1−/− plus LM/Curdlan had to be terminated at days 60 and 36, respectively. The y-axis depicts the increase in footpad thickness (mean ± SD). Data 
were analyzed using Student’s t-test and highlighted if differences are significant (*p < 0.05; BALB/c plus LM compared to BALB/c plus LM/Curdlan). (B) Resistant 
BALB/c mice that had been treated with Curdlan in the presence of L. major parasites were reinfected at day 131 (blue arrow) after primary infection (abbreviated as 
BALB/c plus 1st LM/Curdlan → 2nd LM, blue line, black squares; n = 3). BALB/c mice that had been treated with Curdlan alone 131 days before (abbreviated as 
BALB/c plus 1st Curdlan → 2nd LM, orange line, black circles; n = 3) were also infected. Naïve BALB/c mice were infected (BALB/c plus 1st LM, black line, black 
circle; n = 5), too. The y-axis depicts the increase in footpad thickness (mean ± SD). Data (BALB/c plus 1st LM compared to BALB/c plus 1st LM/Curdlan → 2nd 
LM) were analyzed using two-way ANOVA (*p < 0.05). (c) A delayed-type hypersensitivity (DTH) response is shown, comparing C57BL/6 mice infected with 3 × 106 
parasites (plus LM, black line, black circles; n = 3) with BALB/c mice infected with 3 × 106 parasites plus Curdlan (plus LM/Curdlan, blue line, black squares; n = 3). 
The DTH response was induced 217 days after primary infection as described in Section “Materials and Methods.” The y-axis depicts the increase in footpad 
thickness (mean ± SD), the x-axis hours after antigen application. (D) Relative parasite units (RPU) representing the relative amount of parasites per footpad at days 
3, 14, and 40 after infection are displayed. Infected BALB/c mice (LM, black squares) were compared with BALB/c mice that had been infected with parasites plus 
Curdlan (LM plus Curdlan, black circles). The mean (horizontal line) is shown. Each circle or square represents one analyzed footpad. Data were analyzed using 
Student’s t-test (d3 p = 0.779, d14 p = 0.062, and d40 p = 0.286).
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symptoms of an infection until the termination of the experiment 
120 after the second exposition to Leishmania parasites in the 
absence of Curdlan.
Beside a reinfection, the DTH response is also an accepted 
indicator for the presence of an adaptive T cell-mediated immune 
response (75, 77). In contrast to resistant C57BL/6 mice, BALB/c 
mice hardly generate a measurable DTH reaction after a high-dose 
infection with L. major parasites (52). Using the high-dose model, 
we were able to demonstrate that Curdlan-protected BALB/c mice 
can indeed develop a DTH reaction that is comparable to that 
of resistant C57BL/6 mice (Figure 3C). Consequently, protected 
BALB/c mice mount an adaptive T  cell-mediated immunity 
against L. major parasites that is accompanied by a clear reduc-
tion of the parasite load at the site of infection during the effector 
phase of experimental leishmaniasis (Figure S5 in Supplementary 
Material).
It needs to be mentioned that BALB/c mice can develop 
protective immunity against L. major if they have been infected 
with a low dose of parasites (8). Thus, we had to exclude that 
skin-homing macrophages eliminate the parasites after Curdlan 
contact shortly after infection. A milder course of disease would 
be the artificial consequence. In line with published data (31, 33), 
we were able to demonstrate that macrophages express Dectin-1 
in the presence or absence of parasites (Figures S6A–D in 
Supplementary Material). However, Curdlan activation does not 
induce leishmanicidal mechanisms resulting in the elimination of 
L. major parasites (Figure S7 in Supplementary Material). In line 
with this finding, we were able to show that Curdlan-treated and 
control BALB/c mice show the same parasite burden at the site of 
infection during the early phase (days 3 and 14) of experimental 
leishmaniasis (Figure 3D). At day 40, after infection the beneficial 
effect of Curdlan treatment (the effect of Curdlan treatment on 
the parasite load at day 80 after infection, is shown in Figure S5 in 
Supplementary Material) is slightly indicated but not significant 
(Figure 3D).
In conclusion, we can demonstrate that the presence of 
Curdlan at the time of intradermal infection does not induce 
antigen-unspecific side effects but triggers the modulation of an 
adaptive T-cell response of BALB/c mice in a Dectin-1-dependent 
manner: they develop a resistant phenotype.
cutaneous curdlan application Dampens 
the Th2 response of infected BalB/c 
Mice
The rapid clearance of L. major parasites after a high-dose reinfec-
tion and the positive DTH response of protected BALB/c mice 
(Figures  3B,C) supports the hypothesis that an adaptive Th1 
response was generated. To assess that possibility, Leishmania-
specific IgG subtypes, Th1- and Th2-indicating cytokines, and 
selected transcription factors were characterized.
Protective immunity to L. major infection does not depend on 
the production of specific Abs (78). However, L. major-specific 
IgG responses are an indication for the ability of the host organism 
to mount an antigen-specific immune reaction. In experimental 
leishmaniasis, BALB/c mice mount a Th2 response and produce 
predominantly IgG1, whereas resistant C57BL/6 mice develop a 
Th1 response and an increased production of IgG2c Abs (3, 79). 
An increase in parasite-specific IgG2c is therefore an indicator for 
an ongoing protective Th1 response. In mouse strains with the 
Igh1-a allele, like BALB/c, the IgG2c gene is deleted (80). Thus, we 
determined Leishmania-specific IgG1 and IgG2a subsets in sera of 
BALB/c mice that had been infected in the presence or absence of 
Curdlan. First, we analyzed mice that had not been treated with 
Curdlan. C57BL/6 and BALB/c mice generated Leishmania-specific 
IgG1 25 days after infection (Figure 4A). In contrast, C57BL/6 mice 
produced a significantly higher amount of IgG2a isotypes compared 
to susceptible BALB/c mice (Figure 4B). The infection in the pres-
ence of Curdlan led to an increase in Leishmania-specific IgG2a in 
BALB/c mice (Figure 4C) that also provoked a higher IgG2a/IgG1 
ratio of Leishmania-specific Abs (Figure 4D). Based on these data, 
we conclude that Curdlan treatment might dampen the develop-
ment of a disease-promoting Th2 response in BALB/c mice.
In our study, we used a high-dose infection model and could 
demonstrate that Curdlan application results in protective 
immunity in BALB/c mice (Figure 3). It is important to mention 
that BALB/c mice do not necessarily develop a severe course of 
disease. In low-dose infection models, BALB/c mice develop a 
resistant phenotype, accompanied by the polarization toward a 
Th1-like phenotype (8). Thus, CD4+ T cells from BALB/c mice 
can also differentiate into Th1 cells.
FigUre 4 | The presence of Curdlan at the site of infection modulates the 
humoral immune response of BALB/c mice toward a pronounced production 
of Leishmania-specific IgG2a. C57BL/6 and BALB/c mice were infected with 
a volume of 30 µL PBS containing 3 × 106 Leishmania (L.) major (LM) 
parasites in the presence or absence of Curdlan (c = 50 µg/µL). Blood 
samples were collected 25 days after infection. Leishmania-specific IgG1, 
IgG2a, and IgG2c in sera of infected mice were quantified by ELISA as 
described in Section “Materials and Methods.” (a) Relative ELISA units (REU) 
of Leishmania-specific IgG1 of infected BALB/c and C57BL/6 mice are 
depicted (n = 3). (B) REU of Leishmania-specific IgG2a and IgG2c of infected 
BALB/c and C57BL/6 mice were compared (n = 3; *p < 0.05). (c) REU of 
Leishmania-specific IgG2a of three groups are shown: infected BALB/c mice 
(plus LM), infected BALB/c mice in the presence of Curdlan (plus LM/
Curdlan), and Curdlan-treated BALB/c mice (plus Curdlan) (n = 3; 
*p = 0.043). (D) The ratio of Leishmania-specific IgG2a/IgG1 was calculated in 
BALB/c mice infected with L. major (plus LM) and BALB/c mice infected with 
L. major in the presence of Curdlan (plus LM/Curdlan) (n = 3; *p < 0.05). 
Data were analyzed using the non-parametric Mann–Whitney test. The 
mean ± SD is displayed.
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To address the question, whether protected BALB/c mice show 
a Th1 or Th2 profile, CD4+ T cells were purified from SDLNs and 
analyzed by qRT-PCR. It is commonly accepted that activated 
CD4+ T  cells that receive IL-4 signaling upregulate GATA-
binding protein 3 (GATA3) and become capable of producing 
Th2 cytokines (81, 82). Thus, GATA3 is regarded as an inducer 
for Th2-cell differentiation (83).
We measured the relative expression of GATA3 in CD4+ 
T cells isolated from SDLNs of infected BALB/c mice. These qRT-
PCR data revealed that Curdlan treatment results in a dampened 
expression of GATA3 at day 10 (Figure S8A in Supplementary 
Material), which is significantly reduced at day 28 (Figure S8C 
in Supplementary Material) after infection compared to control 
animals. Furthermore, four out of five Curdlan-treated BALB/c 
mice also showed a clear reduction in IL-4 expression within the 
pool of CD4+ T cells (Figures S8B,D in Supplementary Material). 
Thus, a cutaneous application of Curdlan seems to dampen an 
early IL-4 production within SDLNs. Surprisingly, CD4+ T cells 
isolated from SDLN of Curdlan-treated mice showed a transient 
trend toward a lower expression of the key transcription factor 
T-bet, known to define Th1 cells (84), and of the Th1 cytokine 
IFN-γ at day 10 after infection (Figures S8E,F in Supplementary 
Material). In contrast, at day 28 the expression of T-bet (Figure 
S8 in Supplementary Material) but not of IFN-γ (Figure S8H in 
Supplementary Material) was slightly increased in CD4+ T cells 
of Curdlan-treated BALB/c mice.
A rich body of literature described the fact that Th-cell 
responses  are characterized by the balance of Th1- and Th2-
associated cytokines and not by the relative amount of single 
cytokines such as IFN-γ and IL-4 (85–90). Consequently, we 
calculated the Th1/Th2 ratio based on the relative expression 
levels of GATA3, IL-4, T-bet, and IFN-γ at days 10 and 28 after 
infection. As shown in Figures 5A,B, cutaneous Curdlan applica-
tion was associated with a modulation of the IFN-/IL-4 ratios at 
day 10 and 28, indicating a shift toward a pronounced Th1 and 
a dampened Th2 response at day 28 after infection (Figure 5C). 
The IFN-/IL-4 ratios of BALB/c mice, infected in the absence of 
Curdlan showed no modification (Figure 5D). In line with this 
findings, the ratios of Th1-, Th2-driving transcription factors 
(T-bet/GATA3) was not substantial different at day 10 but signifi-
cant enhanced at day 28 (Figures 5E,F), if mice had been treated 
with Curdlan. Additionally, we were able to demonstrate that this 
Curdlan-induced Th1 polarization increased from day 10 to day 
28 after infection (Figure  5G). T-bet/GATA3ratios of BALB/c 
mice, infected in the absence of Curdlan showed no modification 
(Figure  5H). The Th1 polarization was also accompanied by a 
pronounced IL-17A mRNA expression of CD4+ T cells (data not 
shown).
L. major-harboring Dcs express higher 
levels of Dectin-1 and start to Mature 
after curdlan stimulation
As shown earlier, Dectin-1+ DCs expand at the site of infection 
and within SDLNs after infection with Leishmania parasites 
(Figure 2). A dermal exposure to Curdlan can protect BALB/c 
mice from severe leishmaniasis and induces T  cell-mediated 
immune responses protecting from a high-dose reinfection 
(Figure 3). Cutaneous DCs are known to be crucial for the gen-
eration of adaptive immunity. These professional APCs capture 
parasites or parasite-derived antigens and are able to migrate to 
SDLNs for subsequent antigen presentation to T  cells (14). To 
accomplish these tasks, DCs undergo a maturation program 
accompanied by the expression of surface molecules pivotal for 
FigUre 5 | Lymph node-resident CD4+ T cells from Curdlan-treated BALB/c mice show a shift toward an impaired T helper (Th) 2 response. BALB/c mice were 
infected with a volume of 30 µL PBS containing 3 × 106 Leishmania (L.) major (LM) parasites in the presence (abbreviated as LM plus Curdlan, c = 50 µg/µL) or 
absence of Curdlan (abbreviated as LM). CD4+ T cells were purified at days 10 and 28 after infection, and qRT-PCR was performed to determine the relative mRNA 
levels of target genes referred to GAPDH. The ratios of T-bet/GATA-binding protein 3 (GATA3) and of IFN-γ/IL-4 relative mRNA levels are shown. (a,B) The scatter 
plots depict the relative expression ratio of IFN-γ/IL-4 from the analyzed groups (LM and LM plus Curdlan) at day 10 [(a), *p = 0.042] and day 28 [(B), *p = 0.032]. 
(c,D) The scatter plots depict the relative expression ratios of IFN-γ/IL-4 from the analyzed groups in a time-dependent manner. (c) LM plus Curdlan (***p = 0.0007) 
and (D) plus LM (p > 0.05). (e,F) The scatter plots depict the relative expression ratio of T-bet/GATA3 from the analyzed groups (LM and LM plus Curdlan). Day 10 
[(e), p > 0.05] and day 28 [(F), *p = 0.048] are shown. (g,h) The scatter plots depict the relative expression ratios of T-bet/GATA3 from the analyzed groups in a 
time-dependent manner. (g) LM plus Curdlan (**p = 0.008) and (D) plus LM. Data were analyzed using Student’s t-test. Each symbol represents an individual 
mouse, and the bars indicate the medians.
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migration and of costimulatory molecules (17). Thus, we wanted 
to find out whether Dectin-1+ DCs get infected by parasites and 
if these parasite-harboring Dectin-1+ DCs undergo maturation 
after Curdlan treatment.
BMDCs were cocultured with CFSE-labeled promastigote 
parasites. This allows the differentiation of infected versus 
non-infected BMDCs subsets simultaneously (Figure 6A) (57). 
With this method, we could demonstrate that L. major+ BMDCs 
express a higher level of Dectin-1 compared to uninfected DCs 
(Figures  6B,C). The frequency of Dectin-1-positive BMDCs 
was also significantly higher in the infected BMDC population 
compared to BMDCs that were negative for L. major parasites 
(Figure 6D). Comparable to BMDCs, BMDMs show also a mod-
erate increase in the frequency of Dectin-1+ cells and Dectin-1 
expression intensity after exposition to L. major parasites (Figure 
S6 in Supplementary Material). This would suggest Dectin-1-
mediated host pathogen interactions. Thus, we addressed the 
question whether pathogen-derived carbohydrates can interact 
with C-type lectins and especially with Dectin-1.
The CLRs DC-SIGN (CD209) and the mannose receptor 
C-type 1 (CD206) (91) have been shown to bind Leishmania 
antigens. However, it is unknown whether Dectin-1 recognizes 
L. major-derived molecules. With the help of selected CLR-Fc 
fusion proteins, we were able to demonstrate an interaction of 
L. major parasites with CLEC-9 and MGL-1 that recognizes f-actin 
(92) or galactose, respectively (93) (Figure S9 in Supplementary 
Material). However, a binding of Dectin-1-Fc fusion proteins 
to parasite structures could not be observed (Figure S9 in 
Supplementary Material). Consequently, even though myeloid 
cells such as macrophages and DCs are positive for Dectin-1 
and show a higher Dectin-1 expression after parasite exposition, 
Dectin-1 alone is not crucial for the uptake of L. major parasites, 
because the parasites are negative for the Dectin-1 ligand. The fact 
that Dectin-1−/− phagocytes can still take up parasites supports 
that conclusion (31).
L. major parasites can be detected preferentially in BMDCs 
showing an immature phenotype (Figures  7A,B) and do not 
induce a maturation of infected cells (data not shown). Thus, para-
sites seem to inhibit the maturation of immature and Dectin-1high 
DCs and thereby the subsequent migration to the SDLN (94, 95). 
The incubation of infected BMDCs with Curdlan is accompanied 
by a strong release of TNF-α and IL-6 and a maturation of infected 
BMDCs (Figure 7C; Figure S10 in Supplementary Material). This 
is of special interest, because TNF-α and IL-6 are known to be 
FigUre 6 | Dectin-1 is expressed to a stronger degree by Leishmania (L.) 
major harboring bone marrow-derived dendritic cells (BMDCs) compared to 
non-infected BMDCs. BMDCs were infected with CFSE-labeled L. major 
promastigote parasites. After 24 h, BMDCs were harvested and 
characterized by flow cytometry analysis for the markers CD11c and 
Dectin-1. (a) The dot plot diagram depicts two populations of L. major 
harboring (L. major CFSE+; red square) and not infected (L. major CFSE−; 
blue square) CD11c+ BMDCs. The gates were placed according to the 
isotype controls of not infected BMDCs. (B) The histogram visualizes the 
expression of Dectin-1 of infected (L. major+; red line) and not infected  
(L. major−; blue line) BMDCs. The black line depicts the isotype control. (c) 
The mean fluorescence intensity (MFI) of Dectin-1 expressed by L. major+ 
(red squares) and not infected subsets (L. major−; blue triangles) is shown. 
Each symbol represents an individual mouse. Pooled data of three 
independent experiments are included (*p = 0.018). (D) The frequency of 
Dectin-1+ cells within the infected (L. major+) and not infected (L. major−) 
subsets is displayed as a box plot (n = 5 experiments, **p = 0.0029). Data 
were analyzed using the non-parametric Mann–Whitney test.
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crucial for DC maturation and subsequent priming of T  cells 
(17, 18). Based on the cytokine microenvironment, infected and 
non-infected Curdlan-treated BMDCs express high levels of 
CD86 and thus present a mature phenotype (Figures 7D,E). The 
stimulation of infected BMDCs with Curdlan also induces a strong 
release of T-cell growth factor IL-2 (Figure S10 in Supplementary 
Material). In association with the massive induction of costimula-
tory molecules such as CD86, Curdlan seems to represent an ideal 
adjuvant for efficient priming of L. major-specific T cells (96). In 
line with other published data, we showed that Curdlan activates 
BMDC maturation in a Dectin-1-specific manner (Figure S11 in 
Supplementary Material) (97, 98).
Additionally, we addressed the question whether Dectin-1 
can be detected on Curdlan-activated BMDCs. In this context, 
we were able to demonstrate that immature BMDCs show in gen-
eral a higher Dectin-1 expression compared to mature BMDCs 
(Figure  S12A in Supplementary Material), and the detection 
of surface Dectin-1 is diminished after Curdlan stimulation 
(Figures S12B,E in Supplementary Material). The population of 
mature BMDCs, that is positive for L. major parasites, shows also 
a reduction in the Dectin-1 expression after stimulation with 
Curdlan (compare Q2, Figure S13 in Supplementary Material). 
BMDCs that have been exposed to parasites but do not harbor 
parasites, show no substantial reduction in Dectin-1 expression 
(compare Q2, Figure S13 in Supplementary Material).
In conclusion, we were able to demonstrate that Curdlan 
activation results in a maturation of infected BMDCs in a Dectin-
1-specific manner that in turn might be crucial for the efficient 
priming of antigen-specific CD4+ T cells.
curdlan-activated Dcs show a 
Pronounced Potential of expanding 
Leishmania-specific cD4+ T cells
The adjuvant effect of Dectin-1 ligation in T-cell immunity is 
undisputed, and it has been proven that Curdlan can polarize T-cell 
responses (99, 100). In line with these data, it has been shown that 
anti-Dectin-1 stimulation and the application of microparticulate 
β-glucan conjugates can potentiate an ovalbumin-specific CD4+ 
T-cell response (101, 102). It was also described that Curdlan 
treatment can switch a Th2 to a Th1 response in tumor immunol-
ogy (103). Last but not least, Dectin-1 ligation is discussed to be 
an important checkpoint in Th17-mediated immunity (28, 34, 38, 
97, 104). However, the potential of Curdlan to accelerate the expan-
sion of L. major-specific CD4+ T cells has not been described yet. 
Thus, we isolated CD4+ T cells from SDLN of infected BALB/c mice 
10 days after infection. BMDCs were pulse-infected with L. major 
parasites and incubated in the presence or absence of Curdlan. 
The incubation of CD4+ T cells with Curdlan-activated BMDCs 
resulted in a mild CD4+ T  cell proliferation (Figures  8A,D). 
Proliferation of CD4+ T  cells was substantially increased if 
BMDCs were pulsed with L. major parasites (Figures  8B,D). 
A pronounced enhancement of CD4+ T  cell proliferation was 
achieved by activating L. major-infected BMDCs with Curdlan 
(Figures 8C,D). Consequently, Curdlan is capable of triggering 
the antigen-specific expansion of CD4+ T cells by infected BMDCs 
in a Dectin-1 specific manner (Figure S14 in Supplementary 
Material). Our data are in line with other experimental models 
showing that a Curdlan-induced priming of T cells depends on 
the Dectin-1 pathway (29). Curdlan also enhances the priming 
of antigen-specific T-cells by BMDCs exposed to Leishmania 
antigens (Figure S15 in Supplementary Material).
Supernatants of restimulated T  cells were characterized by 
Multiplex analysis, to determine the expanded Th-cell subset. 
We could show that Curdlan treatment results in a 10-fold pro-
nounced release of IFN-γ, IL-17, and IL-22 compared to control 
mice (Figure S16 in Supplementary Material). Thus, we conclude 
that Curdlan treatment induces a Th1 response in BALB/c mice 
that overlaps with a co-expression of Th17 cytokines (Figure S16 
in Supplementary Material). Of note, the release of Th2 cytokines 
is not substantially modified (Figure S16 in Supplementary 
Material).
FigUre 7 | Leishmania (L.) major (LM) harboring bone marrow-derived dendritic cells (BMDCs) mature after Curdlan stimulation. The effect of Curdlan on BMDC 
maturation was analyzed. 24 h after the Curdlan stimulation, BMDCs were harvested and characterized by flow cytometry using the markers CD11c and CD86. (a) The 
dot plot diagram depicts CD11c+ BMDCs that had been cultured in the absence of Curdlan and CFSE-labeled L. major promastigote (control). The red population 
indicates the isotype control for the anti-CD86 antibody. The quadrants of interest are upper right (Q2, red; L. major CFSE+/CD86+/bright) and lower right (Q3, blue: L. major 
CFSE−/CD86+/bright). The quadrants were placed according to the isotype control and CD11c+ BMDCs negative for CFSE-labeled parasites. (B) The dot plot diagram 
depicts the quadrants of interest of CD11c+ BMDCs incubated with CFSE-labeled parasites (LM). (c) The dot plot diagram depicts the quadrants of interest of Curdlan 
stimulated CD11c+ BMDCs cocultured with CFSE-labeled parasites (LM plus Curdlan). (D) The frequency of L. major CFSE+ and CD86+/bright BMDCs (Q2) is shown.  
(e) The frequency of L. major CFSE− and CD86+/bright (Q3) BMDCs is depicted. The following culture conditions were compared: not infected, not stimulated BMDCs 
[Control, compare (a)], L. major harboring BMDCs [LM, compare (B)], and L. major harboring BMDCs stimulated with Curdlan [LM plus Curdlan, compare (c)]. The box 
plots (D,e) depict pooled data out of two independent experiments (n = 4). Data were analyzed using the non-parametric Mann–Whitney test [(c,D), *p = 0.0286].
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a Mixture of L. major antigens and 
curdlan induces a Milder course of 
experimental leishmaniasis in  
BalB/c Mice
In combination with Curdlan, whole parasites might be used as 
a successful live “vaccine.” This immunization protocol protects 
BALB/c mice upon challenge with a high-dose reinfection from 
severe leishmaniasis (compare Figure 3). Consequently, protected 
BALB/c mice must have developed an adaptive T-cell memory 
response capable of controlling and eliminating L. major parasites 
(75). We investigated whether vaccination of BALB/c mice with 
L. major antigens (SLA) in combination with Curdlan might 
also be a promising approach. We tested the adjuvant potential 
of Curdlan by vaccinating mice intradermally with a mixture of 
SLA and Curdlan. 28 days later, mice were challenged by a high 
dose (3 × 106) of L. major parasites into the contralateral footpad. 
Control mice that had received SLA in the absence of Curdlan 
developed a severe course of leishmaniasis that correlated with 
massive ulceration (compare Figure  3). These control groups 
were not protected, and the experiment had to be terminated 
at day 42 according to the animal health and welfare practices 
(Figures 9A,B).
These results again confirm the already published data that 
the simple administration of antigens does not induce protec-
tion of leishmaniasis in BALB/c mice (105). However, some 
BALB/c mice were partially protected after vaccination with SLA 
combination with Curdlan (Figure 9A). These mice developed 
a milder course of disease. Even though footpad swelling was 
still detectable, the ulceration of lesions was milder and sub-
stantially delayed (Figure 9B). Of note, a complete protection as 
achieved with living parasites could not be induced. The mice 
with delayed but ensuing mild ulcerations and constant footpad 
swelling were sacrificed during the monitoring period according 
FigUre 9 | Course of disease in vaccinated mice challenged with 
Leishmania (L.) major. Soluble L. major antigens (SLA, black square) or SLA 
plus Curdlan (black circle) treated were injected intradermally into the left 
footpad of BALB/c mice. The contralateral right footpad was used for the 
intradermal infection with 3 × 106 L. major parasites 28 days later. (a) The 
increase in footpad thickness after infection is shown (mean ± SD; n = 11 per 
group). (B) The number of mice that do not develop substantial ulcerations 
after intradermal infection into the contralateral hind footpad is depicted 
(n = 11; *p = 0.017). Significances were calculated using a log-rank test.
FigUre 8 | Curdlan stimulation enhances the potential of parasite 
harboring bone marrow-derived dendritic cells (BMDCs) toward the 
expansion of Leishmania-specific CD4+ T cells. BALB/c mice were infected 
with a volume of 30 µL PBS containing 3 × 106 Leishmania (L.) major 
parasites. Ten days after infection, CD3+ T cells were isolated from 
skin-draining lymph nodes (SDLNs) and labeled with CFSE. BALB/c BMDCs 
were harvested at day 10 after ex vivo differentiation with GM-CSF and 
incubated for 24 h with L. major parasites (5:1) in the presence or absence 
of Curdlan (50 μg/200 μL). CFSE-labeled CD3+ T cells and BMDCs (10:1) 
were incubated for 72 h and analyzed by flow cytometry. The proliferative 
(left gate) and resting (right gate) CD4+ T cells are visualized by gates within 
the histogram plots. Following experimental approaches are displayed: (a) 
Curdlan activated but not infected BMDCs (plus Curdlan), (B) infected but 
not activated BMDCs (plus L. major), and (c) Curdlan-activated and 
infected BMDCs (plus L. major; plus Curdlan). The percentage of resting 
and proliferating cells is indicated inside the corresponding gates. (D) The 
proliferation index (described in detail in Section “Materials and Methods”) is 
displayed as a box plot diagram. Pooled data from two independent 
experiments are shown. Data were analyzed using Student’s t-test (Curdlan 
compared with LM, **p = 0.0018 and LM plus Curdlan compared with LM, 
**p = 0.0058; n = 5).
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to the guidelines for the care and use of experimental animals 
(Figure 9B). All analyzed lesions showing a delayed ulceration 
also exhibited a high parasite load (RPU > 1 × 108).
DiscUssiOn
Already in 1970s, β-glucans were used prophylactically or thera-
peutically in various infectious models of obligatory intracellular 
pathogens such as Mycobacterium leprae and Plasmodium berghei 
(106). Since β-glucans have no direct toxic effect on the named 
microbes, it has been suggested that a non-specific activation 
of the reticuloendothelial system was responsible for pathogen 
elimination (106). In experimental VL, β-glucans also elicited a 
strong but non-specific resistance against L. donovani in hamsters 
and BALB/c mice (107, 108). Other groups also demonstrated 
that an i.v. immunization with β-glucans combined with killed 
parasites induced a reduction in the parasite load in visceral 
organs of BALB/c and C57BL/6 mice (46, 109) and that CF-1 
mice developed a milder course of VL, if they had been pre-
treated s.c. or i.v. with β-glucans in combination with killed L. 
donovani parasites (43, 110). These immunization experiments 
demonstrate that a combination of dead parasites and β-glucans 
supports the development of a protective host response in VL. A 
therapeutic effect of the β-glucan Curdlan has also been reported 
in L. donovani (MHOM/IN/1983/AG83)-infected BALB/c mice, 
in association with the generation of Th17 and Th1 cytokines if 
systemically (i.p.) treated with Curdlan (34).
In contrast to VL mouse models, the biological impact of 
β-glucans seems to be heterogeneous in experimental CL. 
For instance, a systemic application (i.v.) of β-glucans was not 
sufficient to modulate the immune response of C57BL/6 mice 
infected with various Leishmania species such as L. mexicana, 
L. braziliensis, and L. garnhami (45). On the other hand, 
L. major (MHOM/IL/80/Fredlin)-infected BALB/c mice develop 
15
Zimara et al. Immunmodulation in Experimental Leishmaniasis
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 263
a milder course of disease after multiple systemic applications 
(i.v. or i.p.) of β-glucans post infection (48). In line with the thera-
peutic potential of Curdlan, (i.p.) pretreatment with β-glucans 
dampened the spreading of L. major (HOM/SA/1983/SAYED) 
parasites in visceral organs of BALB/c mice (111). However, the 
effects of dermal applied β-glucans on the generation of adaptive 
T-cell responses had not been analyzed in detail.
In 2001, the CLR Dectin-1 was identified as the receptor for 
β-glucans (23). Subsequently, macrophages and professional 
antigen-presenting cells were identified as the most prominent 
cell subsets positive for Dectin-1 (112, 113). This finding raised 
the possibility that the activation of Dectin-1+ DC subsets during 
acquisition of adaptive immunity might be modulated by Dectin-
1-dependent pathways. Based on the current model, Langerin− 
dermal DCs are pivotal for the induction of the protective 
Th1-mediated immune response against L. major in experimental 
leishmaniasis (13, 15, 16). Thus, the precise conditioning of those 
DC subsets by Dectin-1-mediated signals might be crucial for 
the induction of adaptive immunity against Leishmania parasites. 
However, it is not known whether a cutaneous infection with 
Leishmania parasites causes an expansion of Dectin-1+ DCs in 
humans or experimental models. Additionally, it was not clear 
whether Dectin-1 signaling results in a pronounced expansion 
and polarization of L. major-specific T cells.
We showed that Dectin-1+ DC subsets expanded in patients 
suffering from CL. Consistent with other reports, we confirmed 
that Dectin-1 is expressed on peripheral blood mDCs of EHCs 
(27, 114). Furthermore, we were able to demonstrate that 
Dectin-1+ peripheral blood mDCs expand in patients suffering 
from CL compared to EHCs. Given that such an expansion of DC 
subsets might also take place at the site of infection and in SDLNs 
of CL patients, Dectin-1+ mDCs might represent promising tar-
gets for a Curdlan-based immunotherapy or vaccination strategy 
in humans. This is especially of interest since Dectin-1+ mDCs 
are discussed to decrease disease-promoting Th2-type responses 
(115). In contrast to mDCs, the expression of Dectin-1 by human 
pDCs is controversially discussed. Unlike mouse Dectin-1, 
human Dectin-1 is also expressed on B cells (27). Consequently, 
an expression of Dectin-1 on lymphoid cell subsets is quite con-
ceivable. Indeed, it was demonstrated by Western blot analysis 
that Dectin-1 is expressed by human CD303+ (BDCA2) pDCs 
(116), whereas in another study CD303 (BDCA2)+ pDCs were 
reported mostly negative for Dectin-1 (117). It can be concluded 
that the frequency of Dectin-1+ DCs is higher within mDCs com-
pared to pDCs. In line with these data, we could detect Dectin-1 
on a small population of Lin−/CD11c−/CD123+ pDCs within the 
blood of EHCs and patients suffering from CL. Nevertheless, this 
extremely small population did not expand after infection. This 
is important for a Dectin-1 ligand-based vaccination or therapy 
because pDCs are supposed to favor disease-promoting Th2-type 
CD4+ T cell responses (118).
Infection with Leishmania parasites is associated with a pro-
nounced myelopoiesis in mammalian hosts (119, 120). However, 
it has not been investigated so far whether this is also accompa-
nied by an expansion of Dectin-1+ DCs. We show that Dectin-1+/
CD11c+ DCs expand within the blood of infected BALB/c and 
C57BL/6 mice, as in patients suffering from CL. CD11c is hardly 
expressed by pDCs in mouse models (71, 72). Therefore, most 
CD11c+/bright DCs belong to the subset of conventional DCs 
including other mDC subsets but not pDCs (73, 74). In addition, 
we found a clear increase in Dectin-1+/CD11c+/bright DCs at the site 
of infection and SDLNs, proving the concept that Dectin-1+ DCs 
represent promising targets for a Curdlan-based immunotherapy.
In vitro analysis was performed to characterize such a 
potentially beneficial impact of Curdlan/Dectin-1 interactions 
on DC-mediated priming of CD4+ Th cells. To accomplish 
these tasks, DCs must undergo maturation to express surface 
molecules pivotal for migration such as CCR7 and costimulatory 
molecules (14, 17). Previous studies have already demonstrated 
that Curdlan can induce DC maturation (121, 122), whereas the 
biological effect of Curdlan on Leishmania-infected DCs was 
unknown. Parasite harboring DCs show an enhanced Dectin-1 
expression but are immature. Curdlan activation resulted in 
the maturation of parasite-harboring DCs and the release of 
DC-activating cytokines. Subsequently, Curdlan-primed infected 
DCs were more potent in expanding antigen-specific T  cells 
compared to DCs that had not been primed with Curdlan. Of 
note, Dectin-1−/− mice (on BALB/c background) were not pro-
tected from severe leishmaniasis by dermal Curdlan application. 
Additionally, Curdlan stimulation could neither mature BMDCs 
from Dectin-1−/− mice nor enhance the priming of antigen-
specific T cells. These findings clearly demonstrate that Dectin-1 
is exclusively responsible for the Curdlan-mediated effects in vivo 
and in  vitro. These data are in line with the already published 
studies, demonstrating a Dectin-1-specific adjuvant effect of 
Curdlan on T cell priming in other experimental models (29, 98, 
123). Consequently, Dectin-1 ligation can be considered as an 
important checkpoint for DC maturation and functionality in 
leishmaniasis.
We would like to point out that surface Dectin-1 is predomi-
nantly expressed by immature DC. This explains why infected 
DCs that in turn display an immature phenotype show a higher 
Dectin-1 mean fluorescence intensity (MFI) compared to 
uninfected DCs. Comparable to macrophages, Curdlan-exposed 
DCs respond with a reduction in the MFI of surface Dectin-1. 
Whether this reduction is due to the Dectin-1/Curdlan complex 
internalization, as described for macrophages, is not clear (124). 
Given the fact that mature DCs in general express lower amounts 
of surface Dectin-1, it cannot be excluded that maturation of 
DCs in general is accompanied by the downregulation of surface 
Dectin-1. In the light of our results, the data from Lima-Junior 
et  al. deserves special consideration. The authors show an 
enhanced Dectin-1 MFI in L. amazonensis infected macrophages 
(33). Given the fact that infected and immature DCs display also a 
higher surface Dectin-1 MFI, it can be suggested that Leishmania 
parasites might favor preferentially Dectin-1+ myeloid cells. 
Indeed, Dectin-1−/− phagocytes respond with a moderate reduc-
tion in the uptake of L. infantum parasites (31). However, we 
found that Dectin-1-Fc fusion proteins do not bind to L. major 
parasites. Thus, a L. major/Dectin-1 interaction can be excluded. 
This is of crucial importance in three aspects: first, L. major para-
sites do not induce Dectin-1 signaling-associated maturation of 
DCs, which might be considered as a smart escape mechanism, 
preventing DC maturation and subsequent T-cell activation. 
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Second, the higher frequency of infected Dectin-1-positive DCs 
is not the result of L. major Dectin-1 interactions, but might be an 
upregulation, based on so far not known mechanisms (33). Third, 
these data might explain the finding that Dectin-1−/− phagocytes 
can still phagocyte L. infantum parasites (31).
Apart from these items discussed earlier, Dectin-1+ mDCs 
might represent useful targets for the induction of a protective 
Th1-polarized CD4+ T-cell response by β-glucans. Indeed, in vivo 
experiments revealed that a dermal application of Curdlan in the 
presence of living parasites induced a resistant phenotype in nor-
mally susceptible BALB/c mice. It is known that CLR signaling 
affects macrophage function in experimental leishmaniasis (31). 
Thus, we had to demonstrate in the high-dose infection model 
that the Curdlan-mediated effect on protective T-cell immunity 
was not the result of an early elimination of parasites at the site of 
infection by dermal macrophages. This would otherwise lead to a 
substantial reduction in parasite numbers shortly after high-dose 
infection. This is of crucial importance because low-dose infected 
BALB/c mice can mount a protective Th1 response (8, 125). Since 
the early parasite load at the site of infection was unaltered in 
the presence of Curdlan, we can exclude Curdlan-mediated early 
effects on L. major clearance by phagocytes. This finding was 
supported by the fact that Curdlan did not induce leishmanicidal 
mechanisms in infected macrophages in vitro. Hence, protection 
in Curdlan-treated BALB/c mice is not mediated by unspecific 
innate immune mechanisms, but an adaptive T  cell-mediated 
response.
The ratio of Th1/Th2 cell and cytokines is crucial for efficient 
T cell-mediated immune responses and the outcome of leishma-
niasis (86). From our data we can conclude that Curdlan treatment 
elicits a clear shift toward a protective Th1-mediated response in 
normally susceptible BALB/c mice. This conclusion is justified 
because Curdlan-treated BALB/c mice developed a resistant 
phenotype and show a clear DTH response that is associated with 
the generation of a T cell memory response, sufficient to protect 
BALB/c mice from a high-dose reinfection (75). The pronounced 
Leishmania-specific IgG2/IgG1 ratio supports also a manifested 
Leishmania-specific Th1 response (3). Furthermore, CD4+ T cells 
isolated from SDLNs of Curdlan-treated infected BALB/c mice 
produced a lower level of IL-4 mRNA, but an increased level of 
cytokines such as IFN-γ and TNF-α after antigen-specific res-
timulation, further supporting a Th1 shift. These data are in line 
with previous studies, showing that early IL-4/IL-4R interactions 
promote Th2-cell polarization and impair the development of a 
Th1 response after infection with L. major (7, 85, 126–131). The 
enhanced release of IL-22 and IL-17 by CD4+ T cells of Curdlan-
treated mice needs a closer view. In mice, IL-17 and IL-22 are 
preferentially associated with Th17-cell differentiation (132). 
This is of interest, because the expressions of IL-17 and IL-22 are 
supposed to be crucial cofactors for Leishmania vaccine-induced 
immunity (133–136).
Successful vaccination programs against Leishmania parasites 
are still problematic. However, whole-organism vaccination 
strategies are most promising (137, 138). This implicates that 
pathogen-associated inflammatory responses at the site of infec-
tion might be crucial for the recruitment of appropriate immune 
cells and the differentiation of antigen-presenting cells, thus 
resulting in protective immunity (14, 139). Whole organisms in 
combination with Curdlan induce a protective immune response 
in normally susceptible BALB/c mice. The classical “vaccination” 
by Leishmania antigens in combination with Curdlan was able 
to dampen the severe progress of disease. However, full protec-
tion could not be achieved. The failure to mount a profound 
and solid adaptive immunity might be explained by the fact that 
Leishmania antigens do not persist at the site of infection and do 
not induce inflammatory immune responses, crucial for driving 
Th1-mediated adaptive immunity. In conclusion, we propose 
that whole-organism application in combination with Curdlan 
represents a promising strategy for the induction of Leishmania-
specific immunity initiated by Dectin-1+ DCs.
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